__timestamp | Galapagos NV | HUTCHMED (China) Limited |
---|---|---|
Wednesday, January 1, 2014 | 9079000 | 26684000 |
Thursday, January 1, 2015 | 20309000 | 29829000 |
Friday, January 1, 2016 | 16945000 | 39578000 |
Sunday, January 1, 2017 | 20559000 | 43277000 |
Monday, January 1, 2018 | 29641000 | 48645000 |
Tuesday, January 1, 2019 | 88258000 | 52934000 |
Wednesday, January 1, 2020 | 162170000 | 61349000 |
Friday, January 1, 2021 | 167218000 | 127125000 |
Saturday, January 1, 2022 | 239528000 | 136106000 |
Sunday, January 1, 2023 | 94252000 | 133175999 |
Igniting the spark of knowledge
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. Selling, General, and Administrative (SG&A) expenses are a key indicator of a company's operational efficiency. This chart compares the SG&A expenses of HUTCHMED (China) Limited and Galapagos NV from 2014 to 2023.
Galapagos NV: From 2014 to 2023, Galapagos NV saw a dramatic increase in SG&A expenses, peaking in 2022 with a 2,500% rise from 2014. However, 2023 marked a significant reduction, dropping by 60% from the previous year.
HUTCHMED (China) Limited: This company experienced a steady increase in SG&A expenses, with a notable 400% rise from 2014 to 2023. The expenses peaked in 2022, showing a consistent upward trend.
These trends highlight the dynamic nature of financial management within the pharmaceutical sector, reflecting strategic shifts and market conditions.
Eli Lilly and Company or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Galapagos NV
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited Trends and Insights
Comparing SG&A Expenses: Cytokinetics, Incorporated vs Galapagos NV Trends and Insights
SG&A Efficiency Analysis: Comparing Opthea Limited and Galapagos NV
Axsome Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Verona Pharma plc vs Galapagos NV
CymaBay Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Amicus Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: HUTCHMED (China) Limited vs Novavax, Inc.